Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 24-02 / BIG 2-02 (SOFT) 

A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer

Suppression of Ovarian Function Trial (SOFT)

DESIGN

please click on the picture to see a larger version

Co-SOFT Substudy


The Cognitive Function Substudy is investigating cognitive function for patients participating in the SOFT trial in selected centers.

SOFT-EST Substudy


The SOFT-EST Substudy investigates estrogen levels at different timepoints during the first 4 years of protocol treatment among patients receiving triptorelin plus either tamoxifen (arm B) or exemestane (arm C).

Results & Publications


Publications

Study Chairs
BIG: Dr. Prue Francis - Melbourne, Australia
US Intergroup: Dr. Gini Fleming - Chicago, USA

Statistician
Dr. Meredith Regan, Dr. Weixiu Luo, Dr. P. Kathryn Gray

Lead Trial Coordinator
Holly Shaw

Data Managers
Karolyn Scott, Monica Greco, Adriana Mora de Karausch, Patricia Gonzalez

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg24-26_STP@fstrf.org

Date of Activation
August 4, 2003

Date of Closure
January 31, 2011

Targeted Accrual
3000 patients

Final Accrual
3066 patients


Substudies Co-SOFT Substudy
Results Publications Results & Publications
Other Pathology


News

09.08.2017:
New publications are available 

11.07.2017:
RACE FOR LIFE - mit Power gegen Krebs am 3. September 2017 in Bern  

10.07.2017:
The next IBCSG Annual Meeting will take place in Barcelona, Spain on March 23 and 24, 2018

All News

 
  Print